Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AZD8205

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

Topoisomerase I inhibitor, B7-H4-targeted antibody-drug conjugate

Related drugs:

‹

irinotecan liposomal (0)

topotecan episcleral (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

›

VTCN1 underexpression	Solid Tumor	VTCN1 underexpression	Solid Tumor	AZD8205 + AZD5305 Sensitive: D – Preclinical AZD8205 + AZD5305 Sensitive : D	AZD8205 + AZD5305 Sensitive: D – Preclinical AZD8205 + AZD5305 Sensitive : D
VTCN1 underexpression	Cholangiocarcinoma	VTCN1 underexpression	Cholangiocarcinoma	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D
VTCN1 underexpression	Ovarian Cancer	VTCN1 underexpression	Ovarian Cancer	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D
VTCN1 underexpression	Triple Negative Breast Cancer	VTCN1 underexpression	Triple Negative Breast Cancer	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D
VTCN1 expression + DDR	Solid Tumor	VTCN1 expression + DDR	Solid Tumor	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D	AZD8205 Sensitive: D – Preclinical AZD8205 Sensitive : D